Akouos Inc. (AKUS) News
Filter AKUS News Items
AKUS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AKUS News Highlights
- AKUS's 30 day story count now stands at 4.
- Over the past 17 days, the trend for AKUS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AKUS are GENE, CVR and LLY.
Latest AKUS News From Around the Web
Below are the latest news stories about AKOUOS INC that investors may wish to consider to help them evaluate AKUS as an investment opportunity.
Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic DiseasesEli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ: AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. |
Lilly and Akouos Announce Expiration of Akouos Tender OfferEli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockh |
10 Most Promising Gene Therapy Companies to WatchIn this piece, we will take a look at the ten most promising gene therapy companies to watch. For more companies, take a look at 5 Most Promising Gene Therapy Companies to Watch. Gene therapy is a revolutionary new technology that has followed the growing advances in computing power. The human body is estimated to […] |
Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss w |
The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVieJ&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog. |
Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A DealsJ&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions. |
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker AkouosLilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million. |
Akouos (AKUS) Surges on $610M Buyout Deal With Eli LillyAkouos (AKUS) is set to be acquired by Eli Lilly for an aggregate amount of $610 million. The deal is expected to close in the fourth quarter of 2022. Stock up. |
AKOUOS (AKUS) was downgraded to a Hold Rating at H.C. WainwrightAKOUOS (AKUS - Research Report) received a Hold rating and price target from H.C. Wainwright analyst Joseph Pantginis today. The company's shares opened today at $7.49.Pantginis covers the Healthcare sector, focusing on stocks such as PDS Biotechnology, Palatin Technologies, and Applied Genetic Technologies. According to TipRanks, Pantginis has an average return of -26.5% and a 23.26% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for AKOUOS with a $23.50 average price target.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $10.23 and a one-year low of $2.32. |
Wall Street Extends Lead After Strong EarningsWall Street is building on yesterday's rally, with the Dow Jones Industrial Average boasting a more than 200-point lead after an impressive round of bank earnings. |